| Name | Title | Contact Details |
|---|
For more than 25 years, Code Blue Corporation has been the industry leading manufacturer of durable emergency communication solutions. The pioneer in developing and producing vandal-resistant Blue Light Emergency Phones at thousands of education, corporate, hospital, airport and municipal locations around the world, Code Blue’s expansion includes the innovation of advanced public address and mass notification systems to provide a complete end-to-end solution. Founded to address the growing need for sophisticated audio security solutions, Code Blue offers American-made Help Point®, Emergency Signaling, Incident Response and Systems Management products that are innovative, rugged, powerful and easily integrated. Code Blue’s evolution continues with the engineering of new software and hardware designed to meet the ever-changing needs of customers who require an advanced level of incident deterrence that establishes a safe environment. No matter where you go, you can feel safe knowing that there is help at the touch of a button.
Spartan Bioscience Inc. is a Nepean, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Medical Cost Management Corp. is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Torax Medical`s core technology applies the unique properties of specialized magnets to precisely restore the barrier function of sphincters. Our technology platform, Magnetic Sphincter Augmentation, uses the attraction forces to augment weak or defective sphincter muscles to treat Gastroesophageal Reflux Disease (GERD) and Accidental Bowel Leakage (fecal or bowel incontinence).
Modern lifestyles and persistent near vision utilization cause a majority of patients to experience the reduced visual acuity and painful symptoms of eye misalignment – headaches, eye strain, neck and shoulder pain, motion sickness and dry eye sensation. Neurolens addresses common binocular vision issues using a three-step process. Step one is efficiently identifying patient symptomology using a basic online symptom screener that every patient can complete in minutes. This information goes directly to the Neurolens Measurement Device, Gen 2—or NMD2—ready for step two, which is accurately and objectively measuring the patient`s level of misalignment. The NMD2 is an objective, accurate and repeatable way to measure eye misalignment as small as 0.01 Prism Diopters. Most importantly, step three is correcting eye misalignment with a proven lens solution. Neurolenses address binocular vision issues by providing a contoured prism lens design that gradually delivers more prism in the lens corridor from distance to near. Neurolenses are proven to have a profound impact on a patient`s visual clarity and comfort. In fact, 93% of patients responded positively to wearing Neurolenses. Over 81% of patients suffering from chronic daily headaches reported their symptoms were substantially reduced or basically gone after wearing Neurolenses for 90 days. Neurolens—recognized in 2022 as one of the 30 fastest growing private companies in the healthcare industry by Inc. Magazine—is confident that appropriately addressing growing binocular vision issues will become a standard of care in this industry, unlocking dramatic patient outcomes and practice growth.